WO2002032862A3 - Use of p38 inhibitors for the treatment of smoke inhalation - Google Patents

Use of p38 inhibitors for the treatment of smoke inhalation Download PDF

Info

Publication number
WO2002032862A3
WO2002032862A3 PCT/US2001/050429 US0150429W WO0232862A3 WO 2002032862 A3 WO2002032862 A3 WO 2002032862A3 US 0150429 W US0150429 W US 0150429W WO 0232862 A3 WO0232862 A3 WO 0232862A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
inhibitors
smoke inhalation
smoke
csbp
Prior art date
Application number
PCT/US2001/050429
Other languages
French (fr)
Other versions
WO2002032862A2 (en
Inventor
Don E Griswold
David C Underwood
Original Assignee
Smithkline Beecham Corp
Don E Griswold
David C Underwood
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Don E Griswold, David C Underwood filed Critical Smithkline Beecham Corp
Priority to JP2002536046A priority Critical patent/JP2004511542A/en
Priority to US10/399,580 priority patent/US20040092532A1/en
Priority to AU2002231283A priority patent/AU2002231283A1/en
Priority to EP01987743A priority patent/EP1337250A2/en
Publication of WO2002032862A2 publication Critical patent/WO2002032862A2/en
Publication of WO2002032862A3 publication Critical patent/WO2002032862A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention is directed to the novel use of a CSBP/p38 inhibitor for the treatment, including prophylaxis of smoke induced pathology resulting from acute and chronic inflammation in the lung.
PCT/US2001/050429 2000-10-19 2001-10-19 Use of p38 inhibitors for the treatment of smoke inhalation WO2002032862A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2002536046A JP2004511542A (en) 2000-10-19 2001-10-19 Use of p38 inhibitors for the treatment of smoke inhalation
US10/399,580 US20040092532A1 (en) 2001-10-19 2001-10-19 Use of p38 inhibitors for the treatment of smoke inhalation
AU2002231283A AU2002231283A1 (en) 2000-10-19 2001-10-19 Use of p38 inhibitors for the treatment of smoke inhalation
EP01987743A EP1337250A2 (en) 2000-10-19 2001-10-19 Use of p38 inhibitors for the treatment of smoke inhalation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24156800P 2000-10-19 2000-10-19
US60/241,568 2000-10-19

Publications (2)

Publication Number Publication Date
WO2002032862A2 WO2002032862A2 (en) 2002-04-25
WO2002032862A3 true WO2002032862A3 (en) 2002-08-22

Family

ID=22911223

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/050429 WO2002032862A2 (en) 2000-10-19 2001-10-19 Use of p38 inhibitors for the treatment of smoke inhalation

Country Status (4)

Country Link
EP (1) EP1337250A2 (en)
JP (1) JP2004511542A (en)
AU (1) AU2002231283A1 (en)
WO (1) WO2002032862A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109557254B (en) * 2018-11-14 2021-08-03 云南中烟工业有限责任公司 Method for establishing standardized cigarette smoke mouse mouth and nose exposure method

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1709965A3 (en) 2001-07-11 2006-12-27 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating cytokine mediate diseases
RU2004132847A (en) * 2002-04-05 2006-08-20 Берингер Ингельхайм Фарма Гмбх Унд Ко.Кг (De) METHOD FOR TREATING HYPERSECRATION OF SLIMAS
CN102060806A (en) 2003-09-11 2011-05-18 iTherX药品公司 Cytokine inhibitors
WO2006137421A1 (en) * 2005-06-21 2006-12-28 Kyowa Hakko Kogyo Co., Ltd. Agent for topical administration
WO2017151409A1 (en) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods
WO2019071144A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. Use of p38 inhibitors to reduce expression of dux4
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997035855A1 (en) * 1996-03-25 1997-10-02 Smithkline Beecham Corporation Novel treatment for cns injuries
WO1999064400A1 (en) * 1998-06-12 1999-12-16 Vertex Pharmaceuticals Incorporated INHIBITORS OF p38

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997035855A1 (en) * 1996-03-25 1997-10-02 Smithkline Beecham Corporation Novel treatment for cns injuries
WO1999064400A1 (en) * 1998-06-12 1999-12-16 Vertex Pharmaceuticals Incorporated INHIBITORS OF p38

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109557254B (en) * 2018-11-14 2021-08-03 云南中烟工业有限责任公司 Method for establishing standardized cigarette smoke mouse mouth and nose exposure method

Also Published As

Publication number Publication date
JP2004511542A (en) 2004-04-15
AU2002231283A1 (en) 2002-04-29
EP1337250A2 (en) 2003-08-27
WO2002032862A2 (en) 2002-04-25

Similar Documents

Publication Publication Date Title
WO2002060869A3 (en) Use of p38 inhibitors for the treatment of inflammation-enhanced cough
JO2311B1 (en) Alkyne-aryl phosphodiesterase-4 inhibitors
ATE276244T1 (en) REPLICATION INHIBITORS OF THE RESPIRATORY SYNZYTIAL VIRUS
WO2002003995A3 (en) Treatment of male sexual dysfunction
ATE183647T1 (en) METHOD OF TREATING INFLAMMATION OF THE LUNGS
ATE297735T1 (en) NEW ACTIVE COMBINATION, CONTAINING AN INHIBITOR OF EPINEPHRINE ABSORPTION AND AN ANTIMUSCArine ACT
MXPA03008485A (en) New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors.
PL361404A1 (en) Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
MY162223A (en) Method for preventing or treating the development of respiratory allergies
WO2001081343A3 (en) Compounds for treating fibromyalgia and chronic fatigue syndrome
BRPI0411050A (en) cold and flu-like symptoms prevention and treatment compositions comprising chelated zinc
BRPI0110506B8 (en) use of IL-18 inhibitors for the treatment and/or prevention of atherosclerosis
WO2002032862A3 (en) Use of p38 inhibitors for the treatment of smoke inhalation
WO2005041864A3 (en) Combination of cyclooxygenase-2 inhibitor and phosphodiesterase 4 inhibitor and method
WO2002072571A8 (en) Pyridinyl pyrazoles useful for the treatment of copd
EE9900118A (en) Use of H +, K + -ATPase Inhibitors in the Treatment of Nasal Polyps
MXPA03011702A (en) Composition comprising a pde-4 inhibitor and h1-receptor antagonist and the use thereof for the manufacture of a medicament for the treatment of respiratory diseases.
AU2001233757A1 (en) Novel use of pulmonary surfactant for the prophylaxis and treatment of chronic pulmonary diseases
MXPA03003592A (en) Use of tolterodine to treat asthma.
AP2003002753A0 (en) Use of salmeterol and fluticasone propionate combination
MXPA03007653A (en) Use of lp82 to treat hematopoietic disorders.
WO2006041808A3 (en) Tafi inhibitors and their use to treat pulmonary fibrosis
EA200100515A2 (en) DIAZEPINOINDOLS FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE LUNG DISEASES
IL158615A0 (en) Modified factor vii in treatment of acute lung injury or acute respiratory distress syndrome
BG106748A (en) Method and compositions for treating pulmonary diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10399580

Country of ref document: US

Ref document number: 2002536046

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001987743

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001987743

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642